134430 <common-name>Podophyllin</common-name> <description>Podophyllin belongs to the 9,9p-dihydroxyaryltetralin lignans, a subclass of aryltetralin lignans within the organic compounds. It is classified under the superclass of lignans, neolignans and related compounds. With an average molecular weight of 1,694 g/mol, Podophyllin is a heavy molecule with the formula C88H92O34.</description> <cas>9000-55-9</cas> <pubchem-id>11979494</pubchem-id> <chemical-formula>C88H92O34</chemical-formula> <weight nil="true"/> <appearance nil="true"/> <melting-point nil="true"/> <boiling-point nil="true"/> <density nil="true"/> <solubility nil="true"/> <specific-gravity nil="true"/> <flash-point nil="true"/> <vapour-pressure nil="true"/> <route-of-exposure nil="true"/> <target nil="true"/> <mechanism-of-toxicity nil="true"/> <metabolism nil="true"/> <toxicity nil="true"/> <lethaldose nil="true"/> <carcinogenicity nil="true"/> <use-source nil="true"/> <min-risk-level nil="true"/> <health-effects nil="true"/> <symptoms nil="true"/> <treatment nil="true"/> <created-at type="dateTime">2026-04-14T17:37:47Z</created-at> <updated-at type="dateTime">2026-05-14T19:02:29Z</updated-at> <interacting-proteins nil="true"/> <wikipedia nil="true"/> <uniprot-id nil="true"/> <kegg-compound-id nil="true"/> <omim-id nil="true"/> <chebi-id nil="true"/> <biocyc-id nil="true"/> <ctd-id nil="true"/> <stitch-id nil="true"/> <drugbank-id>DB09094</drugbank-id> <pdb-id nil="true"/> <actor-id nil="true"/> <organism nil="true"/> <export type="boolean">true</export> <metabolizing-proteins nil="true"/> <transporting-proteins nil="true"/> <moldb-smiles>COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O</moldb-smiles> <moldb-formula>C88H92O34</moldb-formula> <moldb-inchi>InChI=1S/2C22H24O9.2C22H22O8/c2*1-27-16-4-10(5-17(28-2)21(16)29-3)18-11-6-14-15(31-9-30-14)7-12(11)20(24)13(8-23)19(18)22(25)26;2*1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h2*4-7,13,18-20,23-24H,8-9H2,1-3H3,(H,25,26);2*4-7,13,18-20,23H,8-9H2,1-3H3</moldb-inchi> <moldb-inchikey>KOUZYZCESNTXJO-UHFFFAOYSA-N</moldb-inchikey> <moldb-average-mass type="decimal">1693.67</moldb-average-mass> <moldb-mono-mass type="decimal">1692.547000042</moldb-mono-mass> <origin nil="true"/> <state nil="true"/> <logp>0.96</logp> <hmdb-id nil="true"/> <chembl-id nil="true"/> <chemspider-id nil="true"/> <structure-image-file-name nil="true"/> <structure-image-content-type nil="true"/> <structure-image-file-size type="integer" nil="true"/> <structure-image-updated-at type="dateTime" nil="true"/> <biodb-id nil="true"/> <synthesis-reference nil="true"/> <structure-image-caption nil="true"/> <chemdb-id>CHEM130323</chemdb-id> <dsstox-id nil="true"/> <toxcast-id nil="true"/> <stoff-ident-origin nil="true"/> <stoff-ident-id nil="true"/> <susdat-id nil="true"/> <iupac>bis(16-hydroxy-10-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0³,⁷.0¹¹,¹⁵]hexadeca-1,3(7),8-trien-12-one); bis(8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-2H,5H,6H,7H,8H-naphtho[2,3-d][1,3]dioxole-6-carboxylic acid)</iupac> <moldb-polar-surface-area nil="true"/> <moldb-refractivity nil="true"/> <moldb-polarizability nil="true"/> <moldb-rotatable-bond-count nil="true"/> <moldb-acceptor-count nil="true"/> <moldb-donor-count nil="true"/> <moldb-pka-strongest-acidic nil="true"/> <moldb-pka-strongest-basic nil="true"/> <moldb-physiological-charge nil="true"/> <moldb-number-of-rings nil="true"/> <moldb-alogps-logp nil="true"/> <moldb-alogps-logs nil="true"/> <moldb-alogps-solubility nil="true"/> <kingdom>Organic compounds</kingdom> <superklass>Lignans, neolignans and related compounds</superklass> <klass>Aryltetralin lignans</klass> <subklass>9,9p-dihydroxyaryltetralin lignans</subklass> <paper-count type="integer">1842</paper-count> <sync-id>CED0006752</sync-id> <structure-inchikey>KOUZYZCESNTXJO-UHFFFAOYSA-N</structure-inchikey> <structure-fingerprint>80000008000000008000000000008000000000000021000004000000020000010200005000000000000040000000000004000000000400000000000000000080000000000000002000000208000000003000000100020000000000000000100000000400000001000000000000204040000000000000000001010000000400000000000000000000000000000000000000000000000004000010000000080000000240000000800000000000100000440000000001000090000800000000000000100000000020000000000000000000000000000000020000000800000000010000100400808004004100000000000a0000000000000000100</structure-fingerprint> <structure-pattern-fingerprint>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</structure-pattern-fingerprint> <structure-pickle type="binary" encoding="base64">776t3gAAAAAQAAAAAwAAAAAAAAB6AAAAiAAAAIABBgBgAAAAAQMIACgAAAAD AgZAKAAAAAMEBkBoAAAAAwMBBkAoAAAAAwQGQGgAAAADAwEGQCgAAAADBAgA KAAAAAMCBgBgAAAAAQMGQCgAAAADBAgAKAAAAAMCBgBgAAAAAQMGAGAAAAAD AQYAYAAAAAMBBgBgAAAAAwEGAGAAAAACAggAKAAAAAMCBgAoAAAAAwQIACgA AAADAgYAYAAAAAMBCABgAAAAAQEGQCgAAAADBAZAaAAAAAMDAQZAKAAAAAME BkAoAAAAAwQIACgAAAADAgYAYAAAAAICCAAoAAAAAwIGQGgAAAADAwEGQCgA AAADBAYAYAAAAAEDCAAoAAAAAwIGQCgAAAADBAZAaAAAAAMDAQZAKAAAAAME BkBoAAAAAwMBBkAoAAAAAwQIACgAAAADAgYAYAAAAAEDBkAoAAAAAwQIACgA AAADAgYAYAAAAAEDBgBgAAAAAwEGAGAAAAADAQYAYAAAAAMBBgBgAAAAAgII ACgAAAADAgYAKAAAAAMECAAoAAAAAwIGAGAAAAADAQgAYAAAAAEBBkAoAAAA AwQGQGgAAAADAwEGQCgAAAADBAZAKAAAAAMECAAoAAAAAwIGAGAAAAACAggA KAAAAAMCBkBoAAAAAwMBBkAoAAAAAwQGAGAAAAABAwgAKAAAAAMCBkAoAAAA AwQGQGgAAAADAwEGQCgAAAADBAZAaAAAAAMDAQZAKAAAAAMECAAoAAAAAwIG AGAAAAABAwZAKAAAAAMECAAoAAAAAwIGAGAAAAABAwYAYAAAAAMBBgBgAAAA AwEGAGAAAAADAQYAYAAAAAICCABgAAAAAQEGAGAAAAADAQgAYAAAAAEBBkAo AAAAAwQGQGgAAAADAwEGQCgAAAADBAZAKAAAAAMECAAoAAAAAwIGAGAAAAAC AggAKAAAAAMCBkBoAAAAAwMBBkAoAAAAAwQGACgAAAADBAgAaAAAAAMBAQgA KAAAAAMCBgBgAAAAAQMIACgAAAADAgZAKAAAAAMEBkBoAAAAAwMBBkAoAAAA AwQGQGgAAAADAwEGQCgAAAADBAgAKAAAAAMCBgBgAAAAAQMGQCgAAAADBAgA KAAAAAMCBgBgAAAAAQMGAGAAAAADAQYAYAAAAAMBBgBgAAAAAwEGAGAAAAAC AggAYAAAAAEBBgBgAAAAAwEIAGAAAAABAQZAKAAAAAMEBkBoAAAAAwMBBkAo AAAAAwQGQCgAAAADBAgAKAAAAAMCBgBgAAAAAgIIACgAAAADAgZAaAAAAAMD AQZAKAAAAAMEBgAoAAAAAwQIAGgAAAADAQEIACgAAAADAgsAAQABAiACA2gM AwRoDAQFaAwFBmgMBgcgBwgABgloDAkKIAoLAAQMAAwNAA0OAA4PAA8QABAR IBESKAIOEwATFAATFQAVFmgMFhdoDBcYaAwYGSAZGgAaGwAYHGgMHB1oDB4f AB8gICAhaAwhImgMIiNoDCMkaAwkJSAlJgAkJ2gMJyggKCkAIioAKisAKywA LC0ALS4ALi8gLzAoAiwxADEyADEzADM0aAw0NWgMNTZoDDY3IDc4ADg5ADY6 aAw6O2gMPD0APT4gPj9oDD9AaAxAQWgMQUJoDEJDIENEAEJFaAxFRiBGRwBA SABISQBJSgBKSwBLTABKTQBNTgBNTwBPUGgMUFFoDFFSaAxSUyBTVABUVQBS VmgMVldoDElYAFhZIFhaKAJbXABcXSBdXmgMXl9oDF9gaAxgYWgMYWIgYmMA YWRoDGRlIGVmAF9nAGdoAGhpAGlqAGprAGlsAGxtAGxuAG5vaAxvcGgMcHFo DHFyIHJzAHN0AHF1aAx1dmgMaHcAd3ggd3koAgkCaAwdDAAnIGgMOyoART5o DFdIAGRdaAx2ZwARDQAdFWgMLysAOzNoDFdPaAx2bmgMGxcgOTUgVVEgdHAg QhIAAAAGAgkGBQQDBQ8ODREQBhMVHQwNDgYWFxgcHRUFGRgXGxoGICckIyIh BS0sKy8uBjEzOyorLAY0NTY6OzMFNzY1OTgGPkVCQUA/BklKTU9XSAZQUVJW V08FU1JRVVQGXWRhYF9eBmhpbG52ZwZvcHF1dm4FcnFwdHMXBAAAAAAAAAAW </structure-pickle> <structure-indexed-at type="dateTime">2026-09-19T04:49:27Z</structure-indexed-at> </compound>